† Vaccine doses specifically coded as booster or extra doses were excluded. The any dose cohort is a combination of the other three vaccination cohorts persons who received 2 doses were included twice in this cohort, once for each dose. Data were obtained through a single query that was executed by participating health care systems to generate aggregated results.įive cohorts were created using coded EHR data among persons aged ≥5 years: 1) an infection cohort (persons who received ≥1 positive SARS-CoV-2 molecular or antigen test result) 2) a first dose cohort (persons who received a first dose of an mRNA COVID-19 vaccine) 3) a second dose cohort (persons who received a second dose of an mRNA COVID-19 vaccine) 4) an unspecified dose cohort (persons who received an mRNA COVID-19 vaccine dose not specified as a first or second dose) and 5) an any dose cohort (persons who received any mRNA COVID-19 vaccine dose). The study population included persons with documented SARS-CoV-2 testing, viral illness diagnostic codes, or COVID-19 vaccination during the study period. The PCORnet Common Data Model contains information captured from EHRs and other health care data sources (e.g., health insurance claims), including demographic characteristics, diagnoses, prescriptions, procedures, and laboratory test results, among other elements. PCORnet is a national network of networks that facilitates access to health care data and interoperability through use of a common data model across participating health care systems ( ). This study used EHR data from 40 health care systems* participating in PCORnet, the National Patient-Centered Clinical Research Network ( 7), during January 1, 2021–January 31, 2022. These findings support continued use of mRNA COVID-19 vaccines among all eligible persons aged ≥5 years. The risk for cardiac outcomes was likewise significantly higher after SARS-CoV-2 infection than after first, second, or unspecified dose of mRNA COVID-19 vaccination for all other groups by sex and age (RR 2.2–115.2). The incidence of cardiac outcomes after mRNA COVID-19 vaccination was highest for males aged 12–17 years after the second vaccine dose however, within this demographic group, the risk for cardiac outcomes was 1.8–5.6 times as high after SARS-CoV-2 infection than after the second vaccine dose. Risk ratios (RR) were calculated to compare risk for cardiac outcomes after SARS-CoV-2 infection to that after mRNA COVID-19 vaccination. Incidences of myocarditis and myocarditis or pericarditis were calculated after first, second, unspecified, or any (first, second, or unspecified) dose of mRNA COVID-19 (BNT162b2 or mRNA-1273 ) vaccines, stratified by sex and age group. health care systems during January 1, 2021–January 31, 2022, investigators calculated incidences of cardiac outcomes (myocarditis myocarditis or pericarditis and myocarditis, pericarditis, or MIS) among persons aged ≥5 years who had SARS-CoV-2 infection, stratified by sex (male or female) and age group (5–11, 12–17, 18–29, and ≥30 years). Using electronic health record (EHR) data from 40 U.S. Multisystem inflammatory syndrome (MIS) is a rare but serious complication of SARS-CoV-2 infection with frequent cardiac involvement ( 6). Cardiac complications, particularly myocarditis and pericarditis, have been associated with SARS-CoV-2 (the virus that causes COVID-19) infection ( 1– 3) and mRNA COVID-19 vaccination ( 2– 5).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |